



Department of Health Care Finance



PHARMACY & THERAPEUTICS COMMITTEE MEETING  
AGENDA

December 7<sup>th</sup>, 2023

Time: 2:30 PM – 5:30 PM

Online only

Please register at

[https://magellanhealth.zoom.us/webinar/register/WN\\_fdbqoPHFSC-fBpSL9Sm7sg](https://magellanhealth.zoom.us/webinar/register/WN_fdbqoPHFSC-fBpSL9Sm7sg)

- 1) Call to Order Charlene Fairfax, RPh
- 2) Minutes of Previous Meeting Charlene Fairfax, RPh
- 3) Comments from Interested Parties \* Gidey Amare, PharmD, MS
- 4) Clinical Drug Class Reviews Zakia Al-Amin, PharmD, RPh, BCACP  
Ronald E. Kavanagh, BSPHarm, PharmD, PhD, RPh

Angiotensin Modulator Combinations	Hemophilia Agents
Angiotensin Modulators	Hepatitis B Agents
Antianginal Agents (Ranexa)	Hepatitis C Agents
Antibiotics, Topical	HIV and AIDS Treatments
Anticoagulants	Immunomodulators, Atopic Dermatitis
Antihypertensives, Sympatholytics	Immunomodulators, Topical
Antipsoriatics, Oral	Lipotropics, Others
Antipsoriatics, Topical	Lipotropics, Statins
Antiviral Agents, Oral (HSV & Influenza)	Methotrexate
Antiviral Agents, Topical	Platelet Aggregation Inhibitors
Beta-Blockers	Rosacea Agents, Topical
Bile Salts	Sickle Cell Anemia Agents
Calcium Channel Blockers	
- 5) Executive Session (Committee Only) \*\* Charlene Fairfax, RPh  
MMA Representatives
- 6) Final Recommendations of Preferred Drugs \*\*\* MMA Representatives
- 7) Announcement of Next Scheduled P&T Committee Meeting Charlene Fairfax, RPh  
Thursday March 7<sup>th</sup>, 2024
- 8) Final Comments and Adjournment Charlene Fairfax, RPh

\* Individuals wishing to make oral presentations to the Committee will be limited to three (3) minutes

\*\* Closed Session

\*\*\* Open Session